Penumbra (PEN) Cash from Investing Activities (2014 - 2026)
Penumbra's (PEN) quarterly Cash from Investing Activities came in at -$30.6 million in Q1 2026, down 6002.19% year-on-year from $519010.6 in Q1 2025, and up 86.42% on a QoQ basis from -$225.6 million in Q4 2025.
Penumbra (PEN) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Cash from Investing Activities data on file, last reported at -$30.6 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 6002.19% year-over-year to -$30.6 million in Q1 2026; TTM through Mar 2026 was -$434.7 million, a 840.1% decrease from a year earlier, with the FY2025 full-year figure at -$404.6 million, down 621.22% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$30.6 million, up from -$225.6 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for PEN reached as high as $35.7 million in Q3 2024 and fell as low as -$225.6 million in Q4 2025.
- Historically, Cash from Investing Activities has averaged -$18.8 million across 5 years, with a median of $8.6 million in 2022.
- Across the five-year window, Cash from Investing Activities soared 744.73% in 2022 and sank 6002.19% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at $8.6 million in 2022, then soared by 181.25% to $24.3 million in 2023, then tumbled by 145.12% to -$11.0 million in 2024, then slumped by 1959.76% to -$225.6 million in 2025, then surged by 86.42% to -$30.6 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$30.6 million in Q1 2026, -$225.6 million in Q4 2025, and -$162.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.10 Bn | 176.81 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.79 Bn | 125.91 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | -92.80 Mn |
| 6 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | -2.50 Bn |
| 7 | Dexcom | 28.32 Bn | 27.20 Bn | 750.30 Mn | -298.50 Mn |
| 8 | Smith & Nephew | 26.94 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Penumbra | 12.57 Bn | 11.95 Bn | 253.41 Mn | -30.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.63 Mn |
| Mar 31, 2026 | -30.63 Mn |
| Dec 31, 2025 | -225.65 Mn |
| Dec 31, 2025 | -225.65 Mn |
| Sep 30, 2025 | -162.86 Mn |
| Sep 30, 2025 | -162.86 Mn |
| Jun 30, 2025 | -15.58 Mn |
| Jun 30, 2025 | -15.58 Mn |
| Mar 31, 2025 | -502,000.00 |
| Mar 31, 2025 | -502,000.00 |
| Dec 31, 2024 | -10.96 Mn |
| Dec 31, 2024 | -10.96 Mn |
| Sep 30, 2024 | 35.72 Mn |
| Sep 30, 2024 | 35.72 Mn |
| Jun 30, 2024 | 34.47 Mn |
| Jun 30, 2024 | 34.47 Mn |
| Mar 31, 2024 | 18.38 Mn |
| Mar 31, 2024 | 18.38 Mn |
| Dec 31, 2023 | 24.28 Mn |
| Dec 31, 2023 | 24.28 Mn |